

CLAIMS

1. A method for the treatment of glycine-extended gastrin-17-dependent gastrointestinal tumors, comprising administering to a mammal a therapeutically effective amount of an anti-G17 immunogenic composition.
2. The method of claim 1, wherein the immunogen induces anti-G17 antibodies of an effective titer in the immunized mammal which bind and neutralize amidated and glycine-extended gastrin-17.
3. The method of claim 1, wherein the gastrointestinal tumors contain gastrin/cholecystochinin B receptors.
4. The method of claim 1, wherein the gastrointestinal tumors are colorectal adenocarcinomas.
5. The method of claim 1, wherein the mammal is a human.